Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 21-Week, Open-label, Randomized, Controlled, Parallel-group, Multi-center Study Evaluating the Efficacy and Safety of HOE901-U300 Administered According to a Device-Supported Treat-to-target Regimen Versus Routine Titration in Patients With Type 2 Diabetes Mellitus

NCT02585674 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02585674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02585674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 21-Week, Open-label, Randomized, Controlled, Parallel-group, Multi-center Study Evaluating the Efficacy and Safety of HOE901-U300 Administered According to a Device-Supported Treat-to-target Regimen Versus Routine Titration in Patients With Type 2 Diabetes Mellitus
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2015
Completion date
November 30, 2016
Enrollment
151 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus